Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Atacicept in IgA Nephropathy
NCT02808429 · EMD Serono Research & Development Institute, Inc. · PHASE2 · terminated · last registry update 2021-02-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated early as per sponsor decision due to unexpectedly slow enrollment.” | – | Registry record, EMD Serono Research & Development Institute, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF13B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-01-27Also stopped (withdrawn): Matthew C. Baker, tibulizumab (LY3090106) (NCT04563195)
- 2021-10-15Results posted on the registry: Amgen, AMG 570 + AMG 570 Matching Placebo (NCT02618967)
- 2021-08-25Phase 3 first posted: University of Turin, Italy, Belimumab (NCT05020782)
- 2021-06-09Results posted on the registry: GlaxoSmithKline, Belimumab + Rituximab (NCT02631538)
- 2021-01-20Phase 3 first posted: Vera Therapeutics, Inc., Atacicept (NCT04716231)
- 2020-12-28Results posted on the registry: GlaxoSmithKline, Belimumab for IV + Belimumab for SC (NCT04136145)
- 2020-09-24Phase 3 first posted: Matthew C. Baker, tibulizumab (LY3090106) (NCT04563195)
- 2020-07-07Results posted on the registry: Human Genome Sciences Inc., a GSK Company, Placebo plus standard therapy + Belimumab 10 mg/kg plus standard therapy (NCT01639339)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision